IAS 2015

infohep news

• Treatment for people living with HIV and HCV

  Interferon-free hepatitis treatment is highly effective for people with HIV and HCV co-infection in three studies

  Liz Highleyman / 10 August 2015

  Three different interferon-free regimens – sofosbuvir/ledipasvir, AbbVie's 3D regimen and grazoprevir/elbasvir – were well-tolerated and cured more than 90% of participants with HIV and HCV co-infection in three clinical trials, confirming that HIV-positive ...

• Treatment outcomes

  Liver fibrosis regression after hepatitis C treatment linked to reduced complications and death in people with HIV and HCV co-infection

  Liz Highleyman / 06 August 2015

  People with HIV and HCV co-infection, with liver cirrhosis, who achieve sustained virological response (SVR) and experience an improvement in liver fibrosis are less likely to develop liver disease complications or die from ...

• Treatment for people living with HIV and HCV

  Daclatasvir plus sofosbuvir cures HCV for most people with HIV and HCV co-infection in French compassionate use programme

  Liz Highleyman / 05 August 2015

  Interferon-free treatment using daclatasvir (Daklinza) and sofosbuvir (Sovaldi), with or without ribavirin, was well-tolerated and produced sustained virological response rates of 95-100% for people with HIV and HCV co-infection and advanced liver disease, ...

• Treatment for people living with HIV and HCV

  Access to screening and treatment are key issues for hepatitis B and C and HIV/viral hepatitis co-infection

  Liz Highleyman / 04 August 2015

  The development of effective new interferon-free treatment makes it possible to cure more than 90% of people with chronic hepatitis C, including most people with HIV and hepatitis C virus (HCV) co-infection, researchers ...